NCT00783328View on ClinicalTrials.gov

A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Neoplasms

Interventions

DRUG

PF-00299804

Dosage form: 5 mg and 20 mg tablet Dosage: 15 mg, 30 mg and 45 mg, orally, once daily Number of Cycles: until progression or unacceptable toxicity develops.

Trial Locations (1)

Unknown

Pfizer Investigational Site, Sunto-gun